Clinical mastitis in dairy cows: on-farm culture-guided selective therapy vs blanket therapy — POSSIBLE

In dairy cows with clinical mastitis, does on-farm culture-guided selective therapy achieve cure comparable to blanket therapy while reducing antimicrobial use?

Shelf #152 · gate-verified and approved by the developer

POSSIBLE: One large multi-herd randomised trial (422 cows, 449 quarters, 8 commercial dairy farms) answers both halves of the question. Antimicrobial use fell by about half: 51% of culture-guided quarter cases received intramammary antibiotic therapy (study-assigned or secondary) versus 100% of blanket-therapy cases, because gram-negative and no-growth quarters were left untreated after 18–24 hours of on-farm culture. Short-term outcomes showed no statistically significant differences — days to clinical cure 3.2 vs 2.7, bacteriological cure within 21 days 60% vs 71%, new intramammary infection 50% vs 50%, treatment failure 78% vs 81% — and neither did lactation-long outcomes (recurrence, somatic cell count, milk production, culling or death). But 'no significant difference' in a trial whose abstract states no non-inferiority margin is not proof of equivalence — bacteriological cure was numerically 11 percentage points lower with selective therapy — and the trial covered only mild or moderate cases, so this shelf is POSSIBLE, not higher. Drafted Nov 10, 2026 (VetMed build, topic #152); all figures from abstracts fetched and verified at drafting.

Lago 2011 Part I: culture-guided therapy halved intramammary antibiotic use (51% vs 100% of quarter cases) with no significant difference in clinical or bacteriological cure

Randomized controlled trial (record's own publication type) — companion Part I: short-term outcomes

Who: Cattle: dairy cows with mild or moderate clinical mastitis — 422 cows in 449 quarters on 8 commercial dairy farms ranging from 144 to 1,795 cows in Minnesota, Wisconsin, and Ontario, Canada — randomly assigned to a positive-control (blanket) treatment program or an on-farm, culture-based treatment program.

Result: Quarter cases in the positive-control group received immediate on-label intramammary treatment with cephapirin sodium; culture-based cases were treated with cephapirin sodium after 18 to 24h of incubation only if they had gram-positive growth or a mixed infection, and quarters with gram-negative or no growth received no intramammary therapy. The proportion of quarter cases that received intramammary antibiotic therapy because of study assignment was 44% (culture-based) versus 100% (positive-control); secondary antibiotic therapy was given in 19% versus 36%; and the proportion receiving intramammary antibiotic therapy for either reason was 51% versus 100%. There was a tendency toward fewer days of discarded milk with the culture-based program (5.2 vs 5.9 d). No statistically significant differences existed between positive-control and culture-based cases in days to clinical cure (2.7 vs. 3.2 d), bacteriological cure risk within 21 d of enrollment (71 vs. 60%), new intramammary infection risk within 21 d (50 vs. 50%), and treatment failure risk (presence of infection, secondary treatment, clinical mastitis recurrence, or removal from herd within 21 d; 81 vs. 78%).

Watch out: Only mild or moderate clinical mastitis was enrolled — nothing here applies to severe (toxic/systemic) mastitis, where delaying therapy for culture is a different decision. The abstract states no pre-specified non-inferiority margin, so 'no statistically significant difference' must not be upgraded to 'proven equally effective': bacteriological cure was numerically lower with selective therapy (60% vs 71%). Blinding is not stated in the record and is not claimed. First figures in each pair above follow the abstract's ordering (positive-control vs culture-based) except antibiotic-use proportions, which the abstract reports in the same order and which are restated here culture-based first for clarity.

Lago A, Godden SM, Bey R, Ruegg PL, Leslie K. The selective treatment of clinical mastitis based on on-farm culture results: I. Effects on antibiotic use, milk withholding time, and short-term clinical and bacteriological outcomes. J Dairy Sci. 2011;94(9):4441-56. PMID: 21854917. Registry ID: none in the record. MeSH: Animals · Anti-Bacterial Agents · Bacteriological Techniques · Cattle · Cephapirin · Dairying · Female · Lactation · Mastitis, Bovine · Time Factors · Treatment Failure · Treatment Outcome

Lago 2011 Part II: no significant differences for the rest of lactation in recurrence, somatic cell count, milk production, or culling/death

Randomized controlled trial (record's own publication type) — companion Part II: lactation-long outcomes

Who: Cattle: the same randomised trial population as Part I — dairy cows with mild or moderate clinical mastitis, 422 cows in 449 quarters on 8 commercial dairy farms in Minnesota, Wisconsin, and Ontario, Canada, randomly assigned to positive-control blanket therapy or the on-farm culture-based program, followed for the rest of the lactation after enrollment.

Result: No statistically significant differences existed between cases assigned to the positive-control program and cases assigned to the culture-based treatment program in risk and days for recurrence of clinical mastitis in the same quarter (35% and 78 d vs. 43% and 82 d), linear somatic cell count (4.2 vs. 4.4), daily milk production (30.0 vs. 30.7 kg), and risk and days for culling or death events (28% and 160 d vs. 32% and 137 d) for the rest of the lactation after enrollment of the clinical mastitis case.

Watch out: Same trial as Part I, not independent confirmation — the two papers are one study with distinct endpoints, and carding both must not double-count the evidence. Recurrence risk was numerically higher in the culture-based group (43% vs 35%) without reaching significance, which is part of why the shelf stays at POSSIBLE. Follow-up is the remainder of one lactation on North American commercial farms using one on-farm culture system and one intramammary product (cephapirin sodium).

Lago A, Godden SM, Bey R, Ruegg PL, Leslie K. The selective treatment of clinical mastitis based on on-farm culture results: II. Effects on lactation performance, including clinical mastitis recurrence, somatic cell count, milk production, and cow survival. J Dairy Sci. 2011;94(9):4457-67. PMID: 21854918. Registry ID: none in the record. MeSH: Animals · Anti-Bacterial Agents · Bacteriological Techniques · Cattle · Cell Count · Cephapirin · Dairying · Female · Lactation · Mastitis, Bovine · Milk · Recurrence

Synthesis: selective culture-guided therapy cut antibiotic use by half in one large randomised trial; 'comparable cure' is supported but not proven equivalent

Synthesis

Who: Synthesis of the cards above: Lago 2011 Parts I and II — one randomised trial, 422 dairy cows (449 quarters) with mild or moderate clinical mastitis on 8 commercial farms in Minnesota, Wisconsin and Ontario.

Result: The antimicrobial-saving half of the claim is decisive: leaving gram-negative and no-growth quarters untreated reduced the share of cases receiving intramammary antibiotics from 100% to 51%, with a tendency to about a day less discarded milk. The comparable-cure half rests on absence of statistically significant differences across clinical cure time, bacteriological cure, new infection, treatment failure, recurrence, somatic cell count, milk yield and survival — a consistent pattern across many endpoints in a large trial, but with point estimates that sometimes favour blanket therapy (bacteriological cure 71% vs 60%) and no stated non-inferiority margin. That combination earns POSSIBLE: good enough to adopt with monitoring in mild/moderate cases, not proof the two strategies are identical.

Watch out: Do not extend this shelf to severe mastitis (excluded from the trial), to herds without a reliable 18–24h on-farm culture workflow, or to pathogens and products beyond the trial's frame (cephapirin sodium, label use). Delayed treatment of gram-positive cases by up to a day is built into the selective strategy tested.

Synthesis of Lago A et al. PMID: 21854917 and Lago A et al. PMID: 21854918. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.